

SEQUENCE LISTING

<110> PITSON, Stuart, M.
XIA, Pu
MORETTI, Paul. A.
DOBBINS, Julia R.
VADAS, Matthew, A.
WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036
<141> 2003-03-28

<150> PCT/AU03/00388
<151> 2003-03-28

<150> 2003900230
<151> 2003-01-21

<150> 2002951668
<151> 2002-09-19

<150> PS1538
<151> 2002-04-05

<150> PS1621
<151> 2002-04-08

<150> PS1448
<151> 2002-03-28

<160> 14

<170> PatentIn version 3.1

<210> 1
<211> 10
<212> PRT
<213> Homo sapien

<400> 1

Lys Thr Pro Ala Ser Pro Val Val Val Gln
1 5 10

<210> 2
<211> 14
<212> PRT
<213> Homo sapien

<400> 2

Cys Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln
1 5 10

<210> 3
<211> 11
<212> PRT
<213> Homo sapien

<400> 3

Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln
1 5 10

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 4

cggctgctgg cgcccatgaa c

21

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 5

tgtggacctc gaggctgaga agta

24

<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 6

agtgagaagg ctcggcgct gggggag

27

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 7

aagagtggc gccaaagacac 20

<210> 8
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 8

aagagtggga tccaaaggcgc ctgcctcc 28

<210> 9
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 9

aagacacacctg cggcgcccg ttgt 24

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 10

acacacctgccc aaccgggttggt ggtc 24

<210> 11
<211> 19
<212> DNA
<213> Homo sapien

<400> 11

tctcaactggg cagtgggtgc 19

<210> 12
<211> 384
<212> PRT
<213> Homo sapien

<400> 12

Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg
1 5 10 15

Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln
20 25 30

Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser
35 40 45

Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val
50 55 60

Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly
65 70 75 80

Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp
85 90 95

Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ser Leu Pro Ala Gly Ser
100 105 110

Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln
115 120 125

Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Leu Cys Arg
130 135 140

Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly
145 150 155 160

Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp
165 170 175

Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe
180 185 190

Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly
195 200 205

Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala
210 215 220

Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro
225 230 235 240

Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp
245 250 255

Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met

260	265	270
Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe		
275	280	285
Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu		
290	295	300
Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val		
305	310	315
Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly		
325	330	335
Met Phe Ala Val Asp Gly Glu Leu Met Val Ser Glu Ala Val Gln Gly		
340	345	350
Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro		
355	360	365
Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu		
370	375	380

<210> 13
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 13

taaagcttgc caccatggtg agcaag 26

<210> 14
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 14

atggatccat cttgtacagc tcgtccatg 29



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [FAQ](#) | [Glossary](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz Alerts](#) | [News](#) | [Help](#)[Portal Home](#) | [Patents](#) | [Trademarks](#) | [Other](#) | [Sign-Off Authenticated Session](#)**Patent eBusiness**

- [+ Electronic Filing](#)
- [+ Patent Application Information \(PAIR\)](#)
- [+ Patent Ownership](#)
- [+ Fees](#)
- [+ Supplemental Resources & Support](#)

- □ Secured Patent Application Information Retrieval[XML Download](#)[Order Certified Application As Filed](#) [Order](#)

10/509,036

Method of modulating cellular activity

Select New Case	Application Data	Transaction History	Image File Wrapper	Continuity Data	Foreign Priority	Ad
---------------------------------	----------------------------------	-------------------------------------	------------------------------------	---------------------------------	----------------------------------	--------------------

This application is officially maintained in electronic form. To View: Click the and Print: Check the desired document(s) and click PDF.

Patent Information

- [Patent Guidance and General Info](#)
- [+ Codes, Rules & Manuals](#)
- [+ Employee & Office Directories](#)
- [+ Resources & Public Notices](#)

Patent Searches

- [Patent Official Gazette](#)
- [+ Search Patents & Applications](#)
- [+ Search Biological Sequences](#)
- [+ Copies, Products & Services](#)

Other

- [Copyrights](#)
- [Trademarks](#)
- [Policy & Law](#)
- [Reports](#)

Mail Room Date	Document Code	Document Description	Document	Document Description	Document
02-11-2009	LET.	Miscellaneous Incoming Letter			PR
02-11-2009	STATUS.LET	Request for status of Application			PR
02-11-2009	N417	EFS Acknowledgment Receipt			PR
11-13-2008	CRFD	Computer Readable Form (CRF) for Sequence Listing - Defective <i>never rec'd.</i>			PR
10-24-2008	LET.	Miscellaneous Incoming Letter			PR
10-24-2008	STATUS.LET	Request for status of Application			PR
10-24-2008	N417	EFS Acknowledgment Receipt			PR
04-24-2008	SEQ.TXT	Sequence Listing (Text File)			PR
04-24-2008	LET.	Miscellaneous Incoming Letter			PR
04-24-2008	CRFS	CRF Statement Paper and CRF are the same			PR
04-24-2008	SEQLIST	Sequence Listing			PR
03-26-2008	PET.DEC.OIPE	Petition decision routed to the OIPE to act on the decision or continue prosecution.			PR
11-13-2007	CRFD	Computer Readable Form (CRF) for Sequence Listing - Defective			PR
10-26-2007	PET.OP	Petition for review by the Office of Petitions.			PR
10-26-2007	PEFR	Applicant Response to Pre-Exam Formalities Notice			PR
10-26-2007	OATH	Oath or Declaration filed			PR
10-26-2007	ADS	Application Data Sheet			PR
10-26-2007	CRFS	CRF Statement Paper and			PR

			<u>CRF are the same</u>	
10-26-2007	SEQLIST		<u>Sequence Listing</u>	PR
09-18-2007	ARTIFACT		<u>Artifact sheet indicating an item has been filed which cannot be scanned</u>	PR
08-28-2007	PETDEC		<u>Petition Decision</u>	PR
07-11-2007	PET.PCT		<u>Petition for review and processing by the PCT legal office.</u>	PR
05-11-2007	PET.DEC.OIPE		<u>Petition decision routed to the OIPE to act on the decision or continue prosecution.</u>	PR
04-27-2007	CRFL		<u>CRF Sequence Listing Filed</u>	PR
04-16-2007	PET.PCT		<u>Petition for review and processing by the PCT legal office.</u>	PR
07-17-2006	ABN		<u>Abandonment</u>	PR
01-17-2006	CRFD		<u>Computer Readable Form (CRF) for Sequence Listing - Defective</u>	PR
10-11-2005	LET.		<u>Miscellaneous Incoming Letter</u>	PR
10-11-2005	XT/		<u>Extension of Time</u>	PR
03-08-2005	M905		<u>Notice of DO/EO Missing Requirements Mailed</u>	PR
09-27-2004	TRNA		<u>Transmittal of New Application</u>	PR
09-27-2004	SPEC		<u>Specification</u>	PR
09-27-2004	CLM		<u>Claims</u>	PR
09-27-2004	SEQLIST		<u>Sequence Listing</u>	PR
09-27-2004	ABST		<u>Abstract</u>	PR
09-27-2004	DRW		<u>Drawings-only black and white line drawings</u>	PR
09-27-2004	IMIS		<u>Miscellaneous Internal Document</u>	PR
09-27-2004	WCLM		<u>Claims Worksheet (PTO-2022)</u>	PR
09-27-2004	WFEE		<u>Fee Worksheet (PTO-875)</u>	PR
09-27-2004	WFEE		<u>Fee Worksheet (PTO-875)</u>	PR
09-27-2004	ADS		<u>Application Data Sheet</u>	PR
09-27-2004	FRPR		<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR		<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR		<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR		<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	FRPR		<u>Certified Copy of Foreign Priority Application</u>	PR
09-27-2004	371P		<u>Documents submitted with</u>	PR

			<u>371 Applications</u>	
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	371P		<u>Documents submitted with 371 Applications</u>	PR
09-27-2004	IMIS		<u>Miscellaneous Internal Document</u>	PR

If you need help:

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free questions about Patent Application Information Retrieval (PAIR)).*
- *Send general questions about USPTO programs to the USPTO Contact.*
- *If you experience technical difficulties or problems with this application, Business Support or call 1 800-786-9199.*

You can suggest USPTO webpages or material you would like featured on this section by E-mail to the webmaster@uspto.gov. Your suggestions will be considered and may lead to other improvements on the web.

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2008; month=11; day=13; hr=7; min=47; sec=42; ms=190;]

=====

Reviewer Comments:

<110> PITSON, Stuart, M.

XIA, Pu

MORETTI, Paul. A.

DOBBINS, Julia R.

VADAS, Matthew, A.

WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036

<141> 2003-3-28

<150> PCT/AU03/00388

<151> 2003-3-28

<150> 2003900230

<151> 2003-1-21

* * * * *

Please change the dates for numeric identifiers <141> and <151> to the correct format, YYYY-MM-DD.

210> 7

<211> 20

<212> DNA

<213> mammalian

<400> 7

aagagtgggc gccaaagacac

20

Please correct numeric identifier <210> to have both brackets around the number.

```
<210> 8
<211> 28
<212> DNA
<213> mammalian
* * * * * * * * *
<210> 9
<211> 24
<212> DNA
<213> mammalian
* * * * * * * * *
<210> 10
<211> 24
<212> DNA
<213> mammalian

* * * * * * * * *
<210> 11
<211> 19
<212> DNA
<213> mammalian
* * * * * * * * *
<210> 12
<211> 384
<212> PRT
<213> mammalian
* * * * * * * * *
```

For SEQ ID # 1 through 12, numeric identifier <213> can only be one of three choices, "Scientific name, i.e. Genus/species, Unknown or Artificial Sequence." For all sequences using "Unknown or Artificial sequence", for numeric identifier <213>, a mandatory feature is required to explain the source of the genetic material. The feature consists of <220>, which remains blank, and <223>, which states the source of the genetic material. Suggest using "Unknown" for numeric identifier <213> and "mammalian" for numeric identifier <223> in the mandatory feature. Please make all necessary changes.

```
<210> 13
<211> 26
<212> DNA
<213> primers
* * * * *
<210> 14
<211> 29
<212> DNA
<213> primers
* * * * *
```

For SEQ ID # 13 and 14, numeric identifier <213> can only be one of three choices, "Scientific name, i.e. Genus/species, Unknown or Artificial Sequence." For all sequences using "Unknown or Artificial sequence", for numeric identifier <213>, a mandatory feature is required to explain the source of the genetic material. The feature consists of <220>, which remains blank, and <223>, which states the source of the genetic material. Suggest using "Artificial sequence" for numeric identifier <213> and "primers" for numeric identifier <223> in the mandatory feature. Please make all necessary changes.

Application No: 10509036 Version No: 1.0

Input Set:

Output Set:

Started: 2008-11-12 15:22:02.667
Finished: 2008-11-12 15:22:04.649
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 982 ms
Total Warnings: 14
Total Errors: 7
No. of SeqIDs Defined: 14
Actual SeqID Count: 13

Error code	Error Description
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <141>
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>
W 402	Undefined organism found in <213> in SEQ ID (1)
W 402	Undefined organism found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 402	Undefined organism found in <213> in SEQ ID (6)
W 402	Undefined organism found in <213> in SEQ ID (6)
E 212	Invalid Sequence ID Number; Expected 7 as next SeqID but skipped
W 402	Undefined organism found in <213> in SEQ ID (8)
E 249	Order Sequence Error <210> -> <212>; Expected Mandatory Tag: <211> in SEQID (9)
W 402	Undefined organism found in <213> in SEQ ID (9)
W 402	Undefined organism found in <213> in SEQ ID (10)
W 402	Undefined organism found in <213> in SEQ ID (11)
W 402	Undefined organism found in <213> in SEQ ID (12)
W 402	Undefined organism found in <213> in SEQ ID (13)
W 402	Undefined organism found in <213> in SEQ ID (14)

Input Set:

Output Set:

Started: 2008-11-12 15:22:02.667
Finished: 2008-11-12 15:22:04.649
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 982 ms
Total Warnings: 14
Total Errors: 7
No. of SeqIDs Defined: 14
Actual SeqID Count: 13

Error code	Error Description
E 252	Calc# of Seq. differs from actual; 14 seqIDs defined; count=13
E 250	Structural Validation Error; Sequence listing may not be indexable

SEQUENCE LISTING

<110> PITSON, Stuart, M.
XIA, Pu
MORETTI, Paul, A.
DOBBINS, Julia R.
VADAS, Matthew, A.
WATTENBERG, Brian W.

<120> A Method of Modulating Cellular Activity

<130> 229752003700

<140> US 10/509,036
<141> 2003-3-28

<150> PCT/AU03/00388
<151> 2003-3-28

<150> 2003900230
<151> 2003-1-21

<150> 2002951668
<151> 2002-09-19

<150> PS1538
<151> 2002-04-05

<150> PS1621
<151> 2002-04-08

<150> PS1448
<151> 2002-03-28

<160> 14

<170> PatentIn version 3.1

<210> 1
<211> 10
<212> PRT
<213> mammalian

<400> 1

Lys Thr Pro Ala Ser Pro Val Val Val Gln
1 5 10

<210> 2
<211> 14
<212> PRT
<213> mammalian

<400> 2

Cys Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln

1 5 10

<210> 3
<211> 11
<212> PRT
<213> mammalian

<400> 3

Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln
1 5 10

<210> 4
<211> 21
<212> DNA
<213> mammalian

<400> 4

cggctgctgg cgcgcgtaa c 21

<210> 5
<211> 24
<212> DNA
<213> mammalian

<400> 5

tgtggaccc gaggctgaga agta 24

<210> 6
<211> 27
<212> DNA
<213> mammalian

<400> 6

agtgagaagg ctccggcgct gggggag 27

210> 7
<211> 20
<212> DNA
<213> mammalian

<400> 7

aagagtgggc gccaaagacac 20

<210> 8
<211> 28
<212> DNA
<213> mammalian

<400> 8

aagagtggga tccaaaggcgc ctgcctcc 28

<210> 9

<211> 24

<212> DNA

<213> mammalian

<400> 9

aagacacctg cggcgccgt tgtg 24

<210> 10

<211> 24

<212> DNA

<213> mammalian

<400> 10

acacctgccc aaccgggtgt ggtc 24

<210> 11

<211> 19

<212> DNA

<213> mammalian

<400> 11

tctcactggg cagtggtgc 19

<210> 12

<211> 384

<212> PRT

<213> mammalian

<400> 12

Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg
1 5 10 15

Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln
20 25 30

Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser
35 40 45

Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val
50 55 60

Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly
65 70 75 80

Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp
85 90 95

Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ser Leu Pro Ala Gly Ser
100 105 110

Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln
115 120 125

Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Leu Cys Arg
130 135 140

Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly
145 150 155 160

Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp
165 170 175

Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe
180 185 190

Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly
195 200 205

Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala
210 215 220

Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro
225 230 235 240

Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp
245 250 255

Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met
260 265 270

Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe
275 280 285

Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu
290 295 300

Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val
305 310 315 320

Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly
325 330 335

Met Phe Ala Val Asp Gly Glu Leu Met Val Ser Glu Ala Val Gln Gly
340 345 350

Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro
355 360 365

Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu
370 375 380

<210> 13
<211> 26
<212> DNA
<213> primers

<400> 13

taaagcttgc caccatggtg agcaag 26

<210> 14
<211> 29
<212> DNA
<213> primers

<400> 14

atggatccat cttgtacagc tcgtccatg 29